证券代码：300246 证券简称：宝莱特 公告编号：2025-012 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 第八届董事会第二十二次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 广东宝莱特医用科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日以现场会议与通讯表决相结合的方式召开第八届董事会第二十二次会议，会议 通知于 2025 年 4 月 14 日以电子邮件、电话及传真方式送达，公司董事会共有董 事九名，实际出席的董事共九名，符合《公司法》和《公司章程》的规定。 公司全体监事及高级管理人员、保荐代表人胡凤兴列席会议，由公司董事长 燕金元先生主持，经逐项表决，审议通过了以下议案： 一、 审议通过了关于《2024 年度总裁工作报告》的议案 公司董事会依据独立董事出具的《独立董事独立性自查情况表》，对公司现 任独立董事的独立性情况进行评估并出具了《董事会关于独立董事独立性情况的 专项意见》。 1 债券代码：123065 债券简称：宝莱转债 证券代码：300246 证券简称：宝莱特 公告编号：2025 ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-017 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于公司 2024 年度拟不进行利润分配的专项说明 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 一、审议程序 广东宝莱特医用科技股份有限公司（以下简称"公司"）于2025年4月24日 召开第八届董事会第二十二次会议，审议通过了关于《公司2024年度利润分配预 案》的议案，该事项已经公司独立董事专门会议审议通过，尚需提交公司2024 年年度股东大会审议。 二、2024年利润分配预案的基本情况 经致同会计师事务所（特殊普通合伙）出具的《广东宝莱特医用科技股份有 限公司2024年年度审计报告》（致同审字（2025）第442A016608号），公司2024 年度实现归属于上市公司股东的净利润-7,144.13万元，公司2024年度母公司的净 利润-1,302.79万元。截至2024年12月31日，母公司可供分配的利润为47,045.06万 元，合并报表可供分配的利润为43,527.35万元。 根据《上市公司监管指引第3号—上 ...

Financial Performance - In 2024, the company's revenue significantly declined due to external environment factors, business model adjustments, and reduced orders, with management and financial expenses increasing compared to the previous year[4]. - The company's operating revenue for 2024 was ¥1,060,481,198.38, a decrease of 11.18% compared to ¥1,194,001,129.61 in 2023[23]. - The net profit attributable to shareholders for 2024 was -¥71,441,315.88, representing a decline of 9.60% from -¥65,185,130.69 in 2023[23]. - The cash flow from operating activities showed a significant drop to -¥8,636,420.19 in 2024, down 106.69% from ¥129,047,347.24 in 2023[23]. - The basic and diluted earnings per share for 2024 were both -¥0.2721, a decrease of 10.16% from -¥0.2470 in 2023[23]. - Total assets at the end of 2024 were ¥2,498,819,567.37, a decrease of 1.40% from ¥2,534,398,019.03 at the end of 2023[23]. - The net assets attributable to shareholders decreased by 7.03% to ¥1,218,676,708.49 at the end of 2024 from ¥1,310,894,066.37 at the end of 2023[23]. - The company reported a total of ¥25,095,516.50 in non-recurring gains and losses for 2024, compared to ¥16,318,188.91 in 2023[30]. Market Trends and Industry Outlook - The medical device industry remains prosperous, with no signs of overcapacity, continuous decline, or technological substitution[4]. - The medical device industry in China is projected to grow significantly, with the market expected to exceed ¥2.2 trillion by 2030, positioning it as the largest medical device market globally[33]. - The blood purification market in China is expected to grow from CNY 13.4 billion in 2021 to CNY 28.1 billion by 2026, with a compound annual growth rate (CAGR) of 18.6%[37]. - The number of end-stage renal disease patients in China increased from 2.77 million in 2018 to 3.85 million in 2022, and is projected to exceed 5 million by 2026[37]. - The number of patients receiving hemodialysis treatment in China rose from 283,600 in 2013 to 916,600 by the end of 2023, reflecting a compound annual growth rate of over 12%[37]. - The market size of blood dialysis devices and consumables is projected to reach approximately CNY 28 billion by 2026[37]. Product Development and Innovation - The company plans to enhance new product development, actively expand the market, and strengthen internal management to improve core competitiveness and profitability[6]. - The company has established eight consumable bases and a channel platform, positioning itself as a leader in the blood purification industry[42]. - The company has been approved to lead the construction of the "Guangdong Province High-end Blood Purification Equipment Innovation Center" in 2023, focusing on technological innovation[42]. - The company aims to create a kidney medical ecosystem through comprehensive industry chain construction and specialized management[42]. - The company has developed a series of high-tech medical devices, including the Q series multi-parameter monitors and A series multi-parameter monitors, which are recognized as high-tech products in Guangdong Province[57]. - The company is focusing on product innovation and market positioning to drive business growth[49]. - The company has completed product registration for several new medical devices, including the enteral nutrition pump and the video laryngoscope, enhancing its product portfolio[87]. Financial Management and Cost Control - The company will not distribute cash dividends, issue bonus shares, or increase capital through reserves[7]. - The company has initiated a comprehensive cost control strategy, aiming to reduce costs in procurement, production, and logistics, while enhancing operational efficiency[73]. - Sales expenses decreased by 8.49% to ¥142,123,382.85, while management expenses increased by 20.36% to ¥119,882,551.04[86]. - Financial expenses surged by 515.11% to ¥9,161,952.46 due to increased bond interest expenses during the reporting period[86]. - R&D expenses decreased by 10.40% to ¥76,919,684.62[86]. - R&D investment amounted to ¥88,344,833.10, representing 8.33% of operating revenue, an increase from 7.82% in the previous year[88]. Regulatory Compliance and Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring that shareholder meetings are conducted in accordance with legal requirements, with two shareholder meetings held during the reporting period[149]. - The company has implemented strict information disclosure practices, ensuring timely and accurate communication with investors[152]. - The board of directors consists of 9 members, including 3 independent directors, and has held 10 meetings during the reporting period[150]. - The company has maintained complete independence from its controlling shareholders in terms of business, personnel, assets, and financial operations[154]. - The company has not experienced any violations of governance regulations and maintains compliance with relevant laws[153]. Human Resources and Management - The total number of employees at the end of the reporting period is 1,335, with 634 in the parent company and 701 in major subsidiaries[180]. - The company emphasizes a human-centered management approach, focusing on a scientific assessment and incentive system to maximize talent potential[181]. - The company has a training program aimed at enhancing employee skills and fostering a shared corporate culture[182]. - The company has established a mentorship mechanism to ensure the practical application of theoretical training[182]. - The management team includes President Yan Jinyuan and Vice President Liang Jin, with a focus on enhancing operational efficiency[165]. Strategic Initiatives and Future Plans - The company is focused on expanding its market presence through the development of new products and technologies, as well as strategic partnerships[57]. - The company plans to enhance its R&D innovation system and protect its intellectual property to improve product competitiveness[130]. - Future product development will emphasize intelligent, high-margin products for critical care and surgical anesthesia applications[130]. - The company aims to strengthen its brand presence both clinically and in the capital market, striving to become a well-known brand domestically and internationally[133]. - The company is exploring potential mergers and acquisitions to strengthen its position in the healthcare market, particularly in the dialysis segment[72]. Risks and Challenges - Rising raw material costs pose a significant risk to the company's profitability, despite ongoing efforts to control these costs[141]. - The company faces sales risks in overseas markets due to potential changes in exchange rates, economic policies, and trade policies, particularly following the U.S. imposing high tariffs on Chinese goods in April 2025, which has had a minor impact on revenue and gross margin[143]. - Management risks associated with business expansion and new subsidiaries will be addressed through group management and governance structure optimization[140].

Revenue and Profitability - The company's revenue for Q1 2025 was ¥247,732,813.14, a decrease of 7.17% compared to ¥266,864,471.78 in the same period last year[5] - Net profit attributable to shareholders increased significantly by 298.35% to ¥14,448,489.46 from ¥3,627,075.29 year-on-year[5] - The basic and diluted earnings per share rose by 298.54% to ¥0.0546 from ¥0.0137 in the previous year[5] - The company reported a significant increase in operating profit by 31.10%, amounting to ¥6,859,366.88 compared to ¥5,232,235.75 in the previous year[9] - The total profit for the period was ¥17,460,310.47, a substantial increase of 242.36% from ¥5,100,013.56 in the previous year[9] - Net profit increased by 291.14% to 17,328,132.27, driven by reduced expenses and increased subsidiary debt restructuring gains[10] - Comprehensive income rose by 349.66% to 17,871,407.44, influenced by lower expenses and increased subsidiary debt restructuring gains[10] - Earnings per share increased by 291.97% to 0.0546, primarily due to reduced expenses and increased debt restructuring gains[10] Cash Flow and Investments - The net cash flow from operating activities improved by 14.57%, reaching -¥21,108,678.62 compared to -¥24,709,085.13 in the same period last year[5] - Cash inflow from investment activities surged by 274.09% to 278,294,026.26, mainly due to increased recovery of financial product principal[10] - Cash flow from financing activities decreased by 63.33% to 74,789,189.35, attributed to a reduction in bank borrowings compared to the previous year[11] - Cash flow from operating activities showed a net outflow of -21,108,678.62, an improvement from -24,709,085.13 in the previous period[23] - Cash flow from investing activities generated a net inflow of 220,146,787.68, significantly higher than 6,739,937.10 in the previous period[23] - Cash flow from financing activities resulted in a net outflow of -51,991,577.66, compared to a net inflow of 105,340,901.01 in the previous period[23] - The company received cash from the recovery of investments totaling 240,000,000.00, a substantial increase from 66,900,000.00 in the previous period[23] - The company received cash from tax refunds totaling 10,838,352.25, up from 5,645,692.80 in the previous period[23] Assets and Liabilities - Total assets decreased by 4.65% to ¥2,382,570,148.79 from ¥2,498,819,567.37 at the end of the previous year[5] - Current liabilities decreased to CNY 537,758,112.95, down 20.4% from CNY 675,816,871.07[17] - Inventory decreased to CNY 226,718,260.66, down 2.0% from CNY 232,069,806.24[16] - Long-term borrowings increased to CNY 187,360,500.00, up 3.2% from CNY 181,770,000.00[17] - The total equity attributable to shareholders increased to CNY 1,233,668,473.12 from CNY 1,218,676,708.49, reflecting a growth of 1.2%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,605, with the largest shareholder holding 26.72%[12] - The largest shareholder, Yan Jinyuan, holds 70,705,185 shares, with 53,028,889 shares subject to trading restrictions[12] Other Income and Expenses - Non-operating income surged by 44,699.56% to ¥11,038,930.49, primarily due to increased debt restructuring gains[9] - The company received tax refunds of 10,838,352.25, an increase of 91.98% due to higher export tax rebate amounts[10] - Other comprehensive income increased by 219.21% to 543,275.17, mainly due to foreign currency translation differences from overseas subsidiaries[10] - The company reported a significant increase in R&D expenses to CNY 16,404,087.11, compared to CNY 18,430,075.31 in the previous period[19]

广东宝莱特医用科技股份有限公司主营业务是医疗器械产品的研发、生产、销售、服务。主营产品为监 护仪设备、心电图机、脉搏血氧仪、中央监护系统、可穿戴医疗产品、血液透析设备（机）、血液透析 器、透析液过滤器、血液透析粉/透析液、透析管路、穿刺针、消毒液、透析用制水设备、消毒系统、 浓缩液集中配供液系统、腹膜透析设备。 最新一期业绩显示，2024年三季报，公司实现营业收入8.08亿元，同比-15.15%；净利润-13640452.35 元，同比-121.22%，销售毛利率27.18%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)23宝莱特-11.81-25.941.3816.91亿行业平均 46.7547.484.61101.71亿行业中值29.9931.012.3146.06亿1天益医疗-2695.54-2695.541.6920.05亿2硕世生 物-1889.76-1889.761.1637.83亿3澳华内镜-511.89256.744.1053.95亿4诺唯赞-498.11-498.112.2890.13亿5博 晖创新-342.22-210.703.7752.53亿6康泰医学-263.8230.95 ...

债券代码：123065 债券简称：宝莱转债 关于实际控制人部分股份解除质押的公告 广东宝莱特医用科技股份有限公司 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 广东宝莱特医用科技股份有限公司（以下简称"公司"）于近日接到公司实 际控制人王石女士办理部分股份解除质押相关手续的通知，具体事项如下： 二、股东股份累计质押情况 截至公告披露日，本次解除质押后，上述股东及其一致行动人所持质押股份 情况如下： 注：上述股份限售数量为高管锁定股份。截至2025年4月16日公司的股本总数为264,575,527 股计算占总股本比例。上述比例直接相加之和在尾数上可能存在差异，这些差异是因四舍五 股东名 称 是否为控 股股东或 第一大股 东及其一 致行动人 本次解除 质押数量 （股） 占其所 持股份 比例 占公司 总股本 比例 是否为 限售股 （注明 限售股 类型） 是否为 补充质 押 质押开 始日 解除 质押日 期 质权人 王石 是，控股股 东一致行 动人、实际 控制人 3,500,000 53.87% 1.32% 否 否 2024 年 6 月 27 日 2025 年 4 月 1 ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-010 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 2025年第一季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、宝莱转债（债券代码：123065）转股期限为 2021 年 3 月 11 日至 2026 年 9 月 3 日，最新有效的转股价格为人民币 24.02 元/股。 2、2025 年第一季度，共有 0 张"宝莱转债"完成转股（票面金额共计 0 元人 民币），合计转为 0 股"宝莱特"股票（股票代码：300246）。 3、截至2025年第一季度末，公司剩余可转换公司债券（以下简称"可转债"） 数量为2,187,747张，剩余票面总金额为218,774,700元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第15号——可转换公司债券》的有关规定，广东宝莱特医用科技股 份有限公司（以下简称"公司"）现将2025年第一季度可转债转股及公司总股本 变化情况公告如下： 一、可转换公司债 ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-009 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 广东宝莱特医用科技股份有限公司（以下简称"公司"或"宝莱特"）于近日 收到保荐机构财通证券股份有限公司（以下简称"财通证券"）出具的《关于更换 广东宝莱特医用科技股份有限公司持续督导保荐代表人的函》。财通证券系公司 2022年向特定对象发行股份项目（以下简称"该项目"）之保荐机构，财通证券 原委派由亚冬先生、胡凤兴先生担任该项目的持续督导保荐代表人。现由亚冬先 生因工作变动原因，不再担任该项目的持续督导保荐代表人，为保证宝莱特持续 督导工作的正常进行，现委派王康先生（简历附后）担任该项目的持续督导保荐 代表人。本次更换后，宝莱特2022年向特定对象发行股份项目的持续督导保荐代 表人为胡凤兴先生、王康先生，持续督导期限直至持续督导义务结束为止。 公司董事会对由亚冬先生担任公司保荐代表人期间所做出的贡献表示衷心 感谢！ 特此公告。 广东宝莱特医 ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-007 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 第八届董事会第二十一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 根据《广东宝莱特医用科技股份有限公司创业板向不特定对象发行可转换公 司债券募集说明书》（以下简称"募集说明书"）中相关条款，截至 2025 年 3 月 7 日，公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价低于当 期转股价格的 90%。 公司董事会综合考虑公司现阶段的基本情况、股价走势、市场环境等多重因 素，以及对公司长期稳健发展与内在价值的信心，为明确投资者预期，维护全体 投资者的利益，经全体董事认真讨论与审议，同意公司本次不向下修正"宝莱转 债"转股价格，且自本次董事会审议通过后的次一交易日起至未来 6 个月内（即 2025 年 3 月 10 日至 2025 年 9 月 9 日），如再次触发转股价格向下修正条款， 亦不提出向下修正方案。自 2025 年 9 月 10 日起算，若再次触发"宝莱转债"转 股价格的向下修正条款， ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-008 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、截至2025年3月7日，广东宝莱特医用科技股份有限公司（以下简称"公 司"）股票已出现任意连续三十个交易日中至少有十五个交易日的收盘价低于 当期转股价格90%的情形。 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于不向下修正"宝莱转债"转股价格的公告 2、公司于2025年3月7日召开第八届董事会第二十一次会议，审议通过了《关 于不向下修正"宝莱转债"转股价格的议案》，公司董事会决定本次不向下修 正"宝莱转债"转股价格，且自本次董事会审议通过后的次一交易日起至未来6 个月内（即2025年3月10日至2025年9月9日），如再次触发转股价格向下修正条 款，亦不提出向下修正方案。自2025年9月10日起算，若再次触发"宝莱转债" 转股价格的向下修正条款，届时公司将召开董事会会议审议是否行使"宝莱转 债"转股价格的向下修正权利。 公司于2025年3月7日召开了第八届董事会第二十一次会议，审议通过了《关 于不 ...